A detailed history of Strs Ohio transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Strs Ohio holds 5,200 shares of ITOS stock, worth $43,992. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,200
Previous 5,200 -0.0%
Holding current value
$43,992
Previous $77,000 31.17%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$9.89 - $13.64 $55,384 - $76,384
-5,600 Reduced 51.85%
5,200 $70,000
Q4 2023

Jan 30, 2024

SELL
$8.57 - $11.06 $36,851 - $47,558
-4,300 Reduced 28.48%
10,800 $118,000
Q2 2023

Jul 31, 2023

SELL
$12.93 - $18.05 $253,428 - $353,780
-19,600 Reduced 56.48%
15,100 $199,000
Q1 2023

Aug 02, 2023

BUY
$13.02 - $22.62 $255,192 - $443,352
19,600 Added 129.8%
34,700 $472,000
Q1 2023

Apr 27, 2023

BUY
$13.02 - $22.62 $74,214 - $128,934
5,700 Added 19.66%
34,700 $472,000
Q4 2022

Jan 26, 2023

SELL
$17.77 - $21.6 $56,864 - $69,120
-3,200 Reduced 9.94%
29,000 $566,000
Q3 2022

Oct 27, 2022

BUY
$18.6 - $27.25 $24,180 - $35,425
1,300 Added 4.21%
32,200 $613,000
Q2 2022

Jul 25, 2022

BUY
$16.57 - $35.1 $149,130 - $315,900
9,000 Added 41.1%
30,900 $636,000
Q1 2022

Apr 21, 2022

SELL
$31.92 - $47.45 $25,536 - $37,960
-800 Reduced 3.52%
21,900 $704,000
Q4 2021

Jan 24, 2022

BUY
$26.23 - $47.86 $309,514 - $564,748
11,800 Added 108.26%
22,700 $1.06 Million
Q3 2021

Oct 22, 2021

BUY
$23.91 - $29.58 $260,619 - $322,422
10,900 New
10,900 $294,000
Q2 2021

Jul 26, 2021

SELL
$17.9 - $36.1 $255,969 - $516,230
-14,300 Closed
0 $0
Q1 2021

Apr 23, 2021

BUY
$30.86 - $44.2 $357,976 - $512,720
11,600 Added 429.63%
14,300 $488,000
Q3 2020

Dec 14, 2020

BUY
$17.57 - $32.92 $47,439 - $88,884
2,700 New
2,700 $66,000

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $301M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Strs Ohio Portfolio

Follow Strs Ohio and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.